Journal of Thoracic Oncology:
Pathway of the Month
Vascular Endothelial Growth Factor (VEGF) Pathway
Nilsson, Monique PhD*; Heymach, John V. MD, PhD*†
From the Departments of *Cancer Biology and †Thoracic/Head and Neck Medical Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX.
Address for correspondence: John V. Heymach, MD, PhD, Dept. of Thoracic/Head and Neck Medical Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 432, Houston, TX 77030-4009. E-mail: email@example.com
Angiogenesis, the growth of new capillary blood vessels, is critical for the growth and metastatic spread of tumors.1 The search for tumor-derived factors that stimulate angiogenesis led to the identification of vascular endothelial growth factor (VEGF, also known as VEGF-A) as an endothelial mitogen.2 This protein had previously been identified as vascular permeability-inducing factor secreted by tumor cells (VPF, for vascular permeability factor).3 The VEGF gene undergoes alternative splicing to yield at least five different isoforms, ranging in size from 121 to 206 amino acids, of which VEGF165 is the predominant form.
THE VEGF FAMILY
VEGF is now known to be the prototypic member of a family of structurally related dimeric proteins including VEGF-B, VEGF-C, VEGF-D, and VEGF-E, as well as placental-growth factor (PlGF) -1 and -2.4,5 VEGF is essential for development because homozygous or heterozygous deletion of the VEGF gene is embryonically lethal.6 Indeed, VEGF family members are important in physiological angiogenic processes in the adult including wound healing, ovulation, and pregnancy, as well as pathological conditions such as cancer.4 VEGF ligands activate angiogenic programs through binding of several receptors. VEGFR-1 (Flt-1) binds VEGF, VEGF-B, and PlGF -1,2 and promotes recruitment of endothelial progenitors and monocyte migration. VEGFR-2 (Flk-1/KDR) is expressed on nearly all endothelial cells and binds VEGF, VEGF-C, VEGF-D, and VEGF-E. Signal transduction through VEGFR2 has been shown to regulate endothelial cell proliferation, migration, and survival.4 In healthy adults, expression of VEGFR-3 is limited to lymphatic endothelium,7 although VEGFR-3 may also be expressed on tumor-associated blood vessels. Through binding to VEGF-C and VEGF-D, VEGFR-3 is thought to facilitate the outgrowth of lymphatic vessels. Neuropilin (NRP)-1,2 have been demonstrated to be coreceptors for VEGF. NRP-1 binds VEGF165 and PlGF, and NRP-2 binds VEGF165 and VEGF-C.4 Unlike other VEGFRs, NRP-1,2 lack intracellular signaling domains. Although the specific role of NRP-1,2 in angiogenesis is not fully known, NRP-1,2 bind VEGF ligands and enhance their affinity to other VEGFRs.8
VEGF SIGNAL TRANSDUCTION
Although VEGF-A binds VEGFR1 with a higher affinity than VEGFR-2, the biological effects of VEGF-A are thought to be mediated through VEGFR-2. On ligand binding, VEGFR-2 dimerizes, resulting in kinase activation and autophosphorylation of tyrosine residues including Tyr951, Tyr996, Tyr1054, Tyr1175, and Tyr1214.9 Phosphorylation of these residues leads to the activation of signal-transduction molecules phospholipase C-γ (PLC-γ), PI3K, Akt, Ras, Src, and MAPK (Figure 1). Phosphorylation of Tyr1175 results in the binding and phosphorylation of PLC-γ, which subsequently stimulates the release of Ca2+ from internal stores and activation of protein kinase C (PKC). Activation of PKC stimulates the Raf/MEK/ERK pathway, which promotes cell proliferation. Ca2+ mobilization and PKC activation are thought to be key signaling events in VEGF-A–induced vascular permeability via activation of endothelial nitric oxide synthase activity.
PI3K is a heterodimer composed of a p85 regulatory subunit and a p110 catalytic subunit and is critical in the regulation of cell proliferation, migration, and survival. VEGF-A has been shown to stimulate phosphorylation of p85 and enhance PI3K enzymatic activity. The mechanism by which VEGF-A results in activation of PI3K remains unclear, although studies have implicated a role for Src kinases, β-catenin, and VE-cadherin.10,11 VEGFR-2–induced activation of PI3K results in accumulation of phosphatidylinositol-3,4,5-triphosphate, which induces phosphorylation of Akt/PKB. Once activated, Akt/PKB phosphorylates and thus inhibits proapoptotic proteins, BAD, and caspase-9.
Members of the Src family kinases, Src, Fyn, and Yes, are expressed in endothelial cells. After VEGFR-2 autophosphorylation, T-cell–specific adapter binds Tyr951 and then associates with Src. Src kinases regulate actin stress fiber organization and may mediate VEGF-A–induced PI3K activation. Ligand binding to VEGFR-2 also triggers activation of the Ras pathway, initiating signaling through the Raf-1–MEK–ERK signal cascade9 known to be important in growth factor–induced cell proliferation. This activation may occur through multiple routes. The adaptor protein Grb2 is thought to bind pTyr1214 on VEGFR-2, leading to stimulation of the guanine-nucleotide–exchange protein Sos and activation of Ras.9 Alternatively, VEGFR2 activation may promote Shc phosphorylation and binding to Grb2, which may induce Ras activation.12
APPROACHES TO INHIBITING THE VEGF PATHWAY
Several different types of agents have been developed to target the VEGF pathway. These include monoclonal antibodies against VEGF (i.e., bevacizumab) and proteins that bind VEGF such as VEGF Trap, a molecule generated as a fusion protein of the VEGFR extracellular domain and the Fc portion of immunoglobulin G1. Other strategies to target the VEGF pathway include antibodies that block the receptor (IMC-1121b) as well as small-molecule inhibitors of the receptor tyrosine kinase such as sunitinib, sorafenib, and ZD6474 (Table 1). Receptor tyrosine kinase inhibitors are typically administered orally, and because of the structural similarity of the different receptor tyrosine kinases, they generally inhibit multiple kinases in addition to the VEGF receptors. Representative agents targeting the VEGF pathway that are currently in clinical testing are listed in Table 1. The clinical activity of other therapeutic agents such as COX-2 inhibitors, thalidomide, and EGFR inhibitors may also be attributable, at least in part, to reduced expression of VEGF and other proangiogenic factors.
VEGF PATHWAY INHIBITORS: CLINICAL RESULTS
The VEGF pathway has now been validated as a therapeutic target by phase III randomized clinical trials for patients with several different tumor types. In patients with previously untreated non-small cell lung cancer, the addition of bevacizumab to carboplatin and paclitaxel prolonged survival by approximately 2 months compared with treatment with carboplatin and paclitaxel alone.13 Patients with squamous cell histology were excluded from this trial because of a high rate of life-theatening hemoptysis observed in phase II testing of the same regimen. The addition of bevacizumab to chemotherapy has provided benefit in other tumor types as well, including colorectal, breast, and renal-cell cancer.13,14 Sorafenib and sunitinib have also demonstrated significant clinical activity, particularly in renal-cell carcinoma.15,16 Currently, there are ongoing trials using VEGF pathway inhibitors for virtually every type of tumor, and it seems likely that they will become a standard component of treatment for a broad range of tumor types. But despite this progress, major challenges remain. These include developing biomarkers to predict which patients are most likely to respond to treatment; improving management of toxicities, particularly hemoptysis and cardiovascular/thromboembolic complications; and understanding mechanisms of therapeutic resistance so that combinations of VEGF inhibitors with other types of therapy can be more rationally designed.
1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.
2. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306–1309.
3. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–985.
4. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2006;23:1011–1027.
5. Folkman J, Heymach, JV, et al. Tumor Angiogenesis, 7th Ed. Hamilton, Canada: B.C, Decker, 2006.
6. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435–439.
7. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995;92:3566–3570.
8. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735–745.
9. Matsumoto T, Claesson-Welsh L, et al. VEGF receptor signal transduction. Sci STKE 2001;2001:RE21.
10. Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999;98:147–157.
11. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000;100:293–296.
12. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272:32521–32527.
13. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 (Abstract). J Clin Oncol 2006;23:LBA4.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
15. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) (Abstract). J Clin Oncol 2006;23:LBA4510.
16. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16–24.
This article has been cited 9 time(s).
Revue Des Maladies RespiratoiresBevacizumab and non-small cell lung cancer: a new step?Revue Des Maladies Respiratoires
Clinical Cancer ResearchImproved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkersClinical Cancer Research
Expert Review of Anticancer TherapyMode of action and clinical impact of VEGF signaling inhibitorsExpert Review of Anticancer Therapy
Clinical Cancer ResearchCombined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor ResistanceClinical Cancer Research
CarcinogenesisPolymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese populationCarcinogenesis
Current Pharmaceutical Design
Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design, 16():
Bulletin Du Cancer
Angiogenesis and lung cancer
Bulletin Du Cancer, 94():
Cancer Chemotherapy and PharmacologyPhase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN (TM)), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumorsCancer Chemotherapy and Pharmacology
Targeted OncologyAxitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptorTargeted Oncology
© 2006International Association for the Study of Lung Cancer